Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care therapies compared to those with EBV-negative disease. Nanatinostat is a selective class I HDAC inhibitor which induces EBV lytic phase protein generation, activating (val)ganciclovir to its cytotoxic form. This open-label, multicenter, multinational, single-arm, Phase 2 basket study employs a Simon's 2-stage design to allow termination of enrollment into cohorts where treatment appears futile, and will include the following cohorts of patients with EBV+ relapsed/refractory lymphomas:~EBV+ diffuse large B-cell lymphoma (DLBCL, NOS)~Extranodal NK/T-cell lymphoma (ENKTL)~Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL~Hodgkin lymphoma (HL)~Post-transplant lymphoproliferative disorder (PTLD)~HIV-associated lymphomas (Plasmablastic, Burkitt, Hodgkin, DLBCL)~EBV+ lymphoproliferative disorders other than the above
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas